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Abstract The detrimental effects of the winner’s curse,
including overestimation of the genetic effects of associ-
ated variants and underestimation of sufﬁcient sample sizes
for replication studies are well-recognized in genome-wide
association studies (GWAS). These effects can be expected
to worsen as the ﬁeld moves from GWAS into whole
genome sequencing. To date, few studies have reported
statistical adjustments to the naive estimates, due to the
lack of suitable statistical methods and computational
tools. We have developed an efﬁcient genome-wide non-
parametric method that explicitly accounts for the thresh-
old, ranking, and allele frequency effects in whole genome
scans. Here, we implement the method to provide bias-
reduced estimates via bootstrap re-sampling (BR-squared)
for association studies of both disease status and quanti-
tative traits, and we report the results of applying
BR-squaredtoGWASofpsoriasisandHbA1c.Weobserved
over 50% reduction in the genetic effect size estimation for
many associated SNPs. This translates into a greater than
fourfold increase in sample size requirements for successful
replication studies, which in part explains some of the
apparent failures in replicating the original signals. Our
analysis suggests that adjusting for the winner’s curse is
critical for interpreting ﬁndings from whole genome scans
andplanningreplicationandmeta-GWASstudies,aswellas
in attempts to translate ﬁndings into the clinical setting.
Introduction
Parameter estimates, such as the odds ratio (OR) for asso-
ciated SNPs reported in a discovery sample are often
grossly inﬂated as compared to the values observed in the
follow-up sample. For example, in the recent GWAS of
psoriasis (Nair et al. 2009), the OR estimate for rs12983316
on chromosome 19 was reduced from 1.36 in the discovery
sample (1,359 cases and 1,400 controls, p = 2 9 10
-5)t o
1.09 in the follow-up sample (5,048 cases and 5,051 con-
trols, p = 0.027). This phenomenon is known as the Beavis
effect (Xu 2003) or the winner’s curse (Voight and Cox
2004). The magnitude of the winner’s curse in genetic
studies was ﬁrst demonstrated for genome-wide linkage
scans (Go ¨ring et al. 2001) and subsequently for GWAS
(Garner 2007). The winner’s curse is recognized as one of
the major contributing factors to failed replication studies.
For example, four GWAS, all published in the May 2009
issue of Nature Genetics, discussed the effect of the win-
ner’s curse. In particular, the GWAS of severe malaria in
West Africa (Jallow et al. 2009) reported ‘‘because the
effect size was overestimated in initial reports (‘winner’s
curse’) [among other contributing factors]…[the study] did
not identify any of the well-known erythrocyte variants that
A complete list of investigators and members of the research group
appears in N Engl J Med 353, 2643–2653 (2005).
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DOI 10.1007/s00439-011-0948-2have been selected by malaria, other than HbS’’. More
recently, Park et al. (2010) pointed out the importance of the
winner’s curse adjustment in meta-GWAS analysis and in
speciﬁcation of risk prediction models.
Although the detrimental effect of the winner’s curse in
underestimation of the necessary sample size for a suc-
cessful replication study is known, statistical methods and
computational tools suitable for large-scale genome-wide
scans are under-developed. As a result, authors of pub-
lished GWAS usually caution readers about the interpre-
tation of the genetic effects estimated from the discovery
sample (He et al. 2009), or implicate the winner’s curse as
a possible explanation after a replication study has failed
(Jallow et al. 2009).
Extending previous work developed for linkage scans
(Sun and Bull 2005; Wu et al. 2005, 2006), we developed a
bootstrap-based bias-correction method for association
studies that can be applied without collecting additional
data (Faye et al. 2010). In contrast to the likelihood-based
approaches (e.g. Ghosh et al. 2008; Zhong and Prentice
2008), the proposed method adjusts for the effects of
selection due to both the stringent genome-wide signiﬁ-
cance criterion (threshold effect) and the maximization of
the association statistics over the genome (ranking effect).
The ranking effect is not explicitly addressed by the like-
lihood approach in part due to the difﬁculty of specifying a
correct joint likelihood for multiple correlated SNPs gen-
ome wide. However, we demonstrate below that modelling
the threshold effect alone is not adequate for GWAS.
Moreover, our method explicitly accounts for the differ-
ential effect of allele frequency, because the expected bias
is inversely related to the power of the association test,
which is inﬂuenced in turn by the frequency of the asso-
ciated risk allele.
The proposed bootstrap method is conceptually
straightforward, but can be computationally expensive at
the genome-wide level. We implemented the method in a
user friendly and efﬁcient program, BR-squared, suitable to
GWAS of either disease status or quantitative traits. We
applied BR-squared to a recent GWAS of psoriasis (Nair
et al. 2009), and to another of complications of type 1
diabetes in the diabetes control and complications trial
(DCCT) samples (Paterson et al. 2010). In both of these
studies, we observed [50% (sometimes [90%) reduction
in effect estimates for many associated SNPs. We chose to
focus on these two datasets because of the availability of
their built-in replication/follow-up samples which provided
independent estimates of the true underlying genetic
effects. However, we note that the method is designed for
data from the discovery stage alone when a follow-up
sample is generally not available and the required repli-
cation sample size is to be determined based on the genetic
effect size estimated from the discovery stage.
Materials and methods
The psoriasis dataset
Nair et al. (2009) ﬁrst performed a GWAS for psoriasis
using 438,670 SNPs in 1,359 cases and 1,400 controls.
They then applied ranking selection without specifying a
signiﬁcance threshold and conducted a follow-up study of
21 promising SNPs, representing 18 independent loci, in
5,048 cases and 5,051 controls and found supporting evi-
dence for association at 10 loci. They comment that
‘‘Owing to the ‘winner’s curse’, odds ratios estimated in
the discovery sample were larger than those estimated in
the follow-up samples’’ (Table 1; Fig. 1).
Moreover, despite the large sample size of the follow-up
study, 9 SNPs reported in the discovery stage were not repli-
cated(Fig. 2).Usingrs2273668asanexample(naiveOR1.36
andp = 2 9 10
-5inthediscoverystage;replicationOR1.07
and p = 0.12 in the follow-up stage), sample size calculation
based on the naive OR estimate of 1.36 indicates that a suc-
cessful replication study (a = 0.05, power = 80%) requires
only *2K:2K cases:controls. Because the actual replication
study of *5K:5K cases:controls exceeds the sample size
requirement, one might conclude that rs2273668 is a false
positive. However, sample size estimated using the follow-
up OR value of 1.07 implies that the actual replication
study was in fact drastically under-powered, and a much
larger sample of *41K:41K cases:controls ([20-fold
increase) would be required to achieve 80% power at the
0.05 level (sample size calculation). Therefore, this apparent
failure in replication could be explained by unsuspected low
power.
The HbA1c dataset
In the setting of a GWAS of longitudinal repeated mea-
sures of HbA1c in subjects from the DCCT (Paterson et al.
2010), a major locus was identiﬁed in the CONventional
treatment group (nCON = 667) near SORCS1 (10q25.1;
rs1358030; p = 4.66 9 10
-9) via regression analysis of
the average log(HbA1c) value on SNPs with additive
genotype coding (Table 2). In total, 841,342 SNPs, geno-
typed by the Illumina 1 M BeadArray assay, that passed a
set of standard quality control criteria (Paterson et al. 2010)
were assessed for association with HbA1c at
a = 5 9 10
-8, the genome-wide signiﬁcance threshold
(Dudbridge and Gusnanto 2008).
The naive estimate of the regression coefﬁcient for
rs1358030 is bCON.naive = 0.045 (SD 0.008, p = 4.66 9
10
-9). Based on this estimate, the associated SNP
explains *5% of the total phenotypic variation, and a
successful replication study (a = 0.05, power = 80%)
would require 234 samples with a single HbA1c measure
546 Hum Genet (2011) 129:545–552
123(sample size calculation). However, estimates obtained
from the independent INTensive treatment group
(nINT = 637) are markedly smaller: bINT = 0.005 (SD
0.0095, p = 0.606), explaining only *0.05% of the
phenotypic variation and requiring *15 K samples ([50-
fold increase) to achieve 80% power at a = 0.05. Note
that for INT, we used only measures collected at the time
of screening for eligibility for the trial to exclude the
treatment effect, so that the sample could be considered
as a replication dataset.
The genome-wide bootstrap method
The key source of the winner’s curse is the double use of
the same data for both SNP detection and effect estimation.
Ideally, an unbiased effect estimate can be obtained when
there are two independent data sets, one for detection and
the other for estimation. A repeated sample-split approach,
such as bootstrap resampling applied in the original data,
can mimic the separate use of detection and estimation
samples and reduce the variance of the result obtained from
Table 1 Naive, replication and bias-reduced genome-wide BR-squared OR estimates of the ten SNPs associated with psoriasis reported in Nair
et al. (2009)
Chr SNP Pos (Mb) MAF Risk allele p
a Naive OR
b Replication OR
c BR-squared OR
d SD
e Percentage reduction (%)
f
6 rs12191877 31.36 0.14 T 5.73E–053 2.78 2.64 2.78 1.08 0.1
5 rs2082412 158.65 0.21 G 7.00E–010 1.56 1.44 1.39 1.07 26.4
5 rs17728338 150.46 0.06 A 1.88E–007 1.72 1.59 1.24 1.04 60.3
5 rs20541 132.02 0.22 G 5.48E–006 1.37 1.27 1.09 1.03 73.1
6 rs610604 138.24 0.32 G 1.71E–005 1.28 1.19 1.04 1.04 83.6
12 rs2066807* 55.02 0.07 C 1.53E–005 1.68 1.34 1.16 1.03 71.1
1 rs2201841 67.47 0.29 G 2.72E–007 1.35 1.13 1.13 1.04 58.6
9 rs1076160 134.8 0.46 T 2.52E–005 1.26 1.09 1.03 1.05 86.6
19 rs12983316 10.98 0.14 G 2.15E–005 1.37 1.09 1.04 1.04 88.8
2 rs397211 113.6 0.32 T 1.04E–003 1.21 1.08 1.00 1.04 100
* We replaced the imputed SNP rs2066808 with the nearby SNP rs2066807 that is in perfect LD (r
2 = 1 in Hapmap phase II samples)
a The allelic association p value using the discovery samples (1,357 cases and 1,400 controls) from dbGaP
b The naive estimate of the OR using the discovery samples without accounting for the ranking effect as reported in column 7 of Table 2 of Nair
et al. (2009)
c The OR estimated from the independent follow-up samples as reported in column 11 of Table 2 of Nair et al. (2009)
d The bias-reduced OR estimate provided by BR-squared using 1,000 level 1 bootstrap samples
e SD of the BR-squared OR estimate based on 100 level 2 bootstrap samples
f The percentage reduction in the estimates as measured by 1-log(bootstrap.OR)/log(naive.OR)
Fig. 1 Naive (red), replication
(dark blue), genome-wide BR-
squared (light blue) and single-
SNP likelihood (orange)
estimates of the log(OR) of the
ten SNPs reported in Table 2 of
Nair et al. (2009). These ten
SNPs were associated with
psoriasis in the discovery stage
and had replication p\0.05
and the effect estimates in the
same direction as the discovery
stage
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123a single sample-split approach (Sun and Bull 2005; Faye
et al. 2010). A detailed development and evaluation of the
method for GWAS can be found in Faye et al. (2010). In
essence, the genome-wide bootstrap estimate is constructed
in the following way.
The original selection procedure (e.g. signiﬁcance thresh-
old,ranking,eitherorboth)isrepeatedinB1 level1bootstrap
samples drawn from the original dataset. For each selected
SNP, the effect size is estimated in the observations in the ith
bootstrap sample (bDi) and also in the observations not
included in the bootstrap sample (bEi, ‘‘out-of-bootstrap’’
sample), where i = 1,…,B1. The estimate of bias for the kth
ranked SNP selected in the original sample is the average
differencebetweenbDiandbEiforthekthrankedSNPselected
in each bootstrap repetition, adjusted for the minor allele fre-
quency (MAF). The bias-reduced bootstrap shrinkage esti-
mate for thekth rankedSNPselected in theoriginal sampleis
bbootstrap k ðÞ¼bNðkÞ 
1
B1
P B1
i¼1
bDi k ðÞ bEi k ðÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2pik ðÞ1 pik ðÞ
   q   
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2p k ðÞ1 p k ðÞ
   q ;
where bN(k) is the naive estimate for the kth ranked SNP
selected in the original sample with MAF p(k). Note that in
the genome-wide setting the SNP selected in the bootstrap
sample has the same rank as the SNP selected in the ori-
ginal data, but may or may not be the same SNP. Thus, pi(k)
is the MAF for the kth ranked SNP selected in the ith
bootstrap sample. This estimator is further improved by
correcting for the negative correlation between bDi and bEi
(Faye et al. 2010).
The standard deviation (SD) of the bootstrap estimate is
estimated by obtaining B2 level 2 bootstrap samples from
the original dataset to serve as a set of hypothetical ‘‘ori-
ginal’’ datasets. In each of these B2 samples, the associa-
tion analysis is performed following the original selection
procedure, and the same bootstrap estimation method as
described above is applied to each of the j samples,
j = 1,…,B2. A log transformation is applied to the level 2
shrinkage estimates to achieve approximate normality, and
the SD of these estimates is used to construct a symmetric
conﬁdence interval (CI), which is then back-transformed to
the original scale (Faye et al. 2010).
A single-locus bootstrap estimate may be obtained by
applying the above procedure to a dataset that contains
only the SNP of interest, ignoring the information provided
by other SNPs correlated due to linkage disequilibrium
(LD). Faye et al. (2010) show that the single-locus
Fig. 2 Naive (red), replication
(dark blue), genome-wide BR-
squared (light blue) and single-
SNP likelihood (orange)
estimates of the log(OR) of the
nine SNPs reported in the
supplementary Table 2 of Nair
et al. (2009). These nine SNPs
were associated with psoriasis
in the discovery stage, but had
replication p[0.05 or the
effect estimates in the opposite
direction as the discovery stage
Table 2 Naive, replication and bias-reduced genome-wide BR-squared regression coefﬁcient (b) estimates of the signiﬁcant SNP associated
with HbA1c in the DCCT samples
Chr SNP Pos
(Mb)
MAF Risk
allele
p value
a Naive beta
b Replication
beta
c
BR-squared
beta
d
SD
e Percentage
reduction
f
10 rs1358030 108.1 0.36 C 4.66E–09 0.045 0.005 0.003 0.013 93%
a The association p value using the 667 samples from the DCCT CON group
b The naive estimate of the regression coefﬁcient beta using the 667 CON samples without accounting for the threshold effect
c The beta estimated from the independent 637 samples from the DCCT INT group
d The bias-reduced beta estimate provided by BR-squared using 1,000 level 1 bootstrap samples and with a = 5 9 10
-8
e SD of the BR-squared beta estimate based on 100 level 2 bootstrap samples
f The percentage reduction in the estimates as measured by 1 - bootstrap.beta/naive.beta
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123bootstrap and likelihood-based approaches perform simi-
larly well, but both are outperformed by the genome-wide
bootstrap method. The genome-wide bootstrap point esti-
mate has a smaller variance and smaller root mean squared
error (RMSE) than the likelihood method, and the genome-
wide bootstrap CIs are narrower and achieve better cov-
erage than the likelihood CIs.
Method implementation as BR-squared
Although the bootstrap procedure is computationally
intensive, the highly efﬁcient software package, BR-
squared, that we developed can feasibly compute the bias-
reduced effect estimates for typical GWAS of 1M SNPs
and 2K individuals for example.
BR-squared is open-source and was developed in C??,
using a small part of the PLINK (Purcell et al. 2007) code
for the association tests. It is designed to be user-friendly,
easy to apply and familiar to the users of PLINK, and it is
portable across Linux, Windows or Mac OS environments.
BR-squared contains highly optimized code and can handle
arbitrarily large datasets, with similar memory require-
ments as PLINK. Data are read from PLINK formatted
ﬁles, containing either case–control or quantitative phe-
notypes with or without covariates and an arbitrary number
of SNPs and individuals. A variety of association tests can
be speciﬁed for binary phenotypes, including allelic, trend
and genotypic tests or Wald tests in the logistic model. For
quantitative traits, a linear model is used.
Sample size calculation
In a case–control association study, let p.case and p. con-
trol be the allele frequencies of the risk allele in cases and
controls and assume an equal number of cases and controls
and an one-sided allelic test (i.e. requiring consistency of
the effect direction), the sample size required for a suc-
cessful replication study at a level with 1 - h power is
where p = (p.case ? p.control)/2, and Q   ðÞis the quan-
tile function of the standard normal distribution (Ziegler
and Konig 2006). Note that p.case = OR 9 p.control/
(OR 9 p.control ? (1 - p.control)).
In a quantitative association study, assume that the asso-
ciation analysis is performed via linear regression,
Y * b0 ? bX,whereYisthequantitativephenotypeandXis
theSNPgenotypecoding.Fornotationsimplicity,letbbethe
parameter estimate and (Sb)
2 the associated variance esti-
mate. The test statistic, Z = b/Sb, is approximately normally
distributed, N(l, 1), assuming that the null and alternative
variances are similar. The sample size required to achieve
signiﬁcance at the a level with 1 - h power depends on
l ¼  Q a ðÞ   Q h ðÞ :
Furthermore, using subscript c for the current study and f
for the planned future replication study, and letting
r
2 = Var(Y), we can show that
l ¼ E
bf
Sbf
  
 
E½bf 
E½Sbf 
 
bc ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
r2
f P
Xif  Xf ðÞ
2
r
 
bc
rc
rc
rf
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ P
Xic    Xc ðÞ
2
nc
s
ﬃﬃﬃﬃ
nf
p
¼
bc
Sbc
rc
rf
ﬃﬃﬃﬃﬃ
nf
nc
r
:
Thus, the sample size required for future replication is
nf  
rf
rc
   2 Sbc
bc
   2
l2nc; ð1Þ
where nc is the sample size of the current study.
Assuming rf = rc, the sample size calculation can be
simpliﬁed as
nf  
Sbc
bc
   2
l2nc: ð2Þ
However, if the current study used the mean of T
measures of Y while the future study is to use a single
measure of Y, as in the DCCT example, then
rf
rc
   2
¼
T2
T þ2
P
i\jqYiYj
¼Teff; andnf  Teff  
Sbc
bc
   2
l2nc;
ð3Þ
where qYiYj is the correlation between longitudinal phe-
notype observations, and Teff is the effective number of
observations depending on the correlation. For example, if
observations are independent of each other, qYiYj = 0,
then Teff = T, and the sample size required for future
study using a single measure must be increased by T fold
when compared with a study using the average of
T measures. If observations are perfectly correlated to
each other, Teff = 1 and having more observations does
2  
 Q a ðÞ  
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2p 1   p ðÞ
p
  Q h ðÞ  
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
p:case 1   p:case ðÞ þ p:control 1   p:control ðÞ
p    2
p:case   p:control ðÞ
2 ;
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123not add statistical efﬁciency. Then, sample size calcula-
tions follow (2).
In the DCCT example (Paterson et al. 2010), the intra-
class correlation coefﬁcient between consecutive quarterly
HbA1c values (in the CON group) was 0.79, falling to 0.42
for values measured 3 years apart. The estimate of Teff was
approximate 2. This value was then used for sample size
calculation based on the naive estimate obtained from the
CON group that had an average of 26 observations per
individual. Teff = 1 was used for sample size calculation
based on the follow-up estimate obtained from the INT
group since only the single measure at the eligibility time
point was used for the analysis.
In general, the sample size n required for a successful
replication study is inversely proportional to the effect size
b such that n * 1/(b
2), where b is the log(OR) or the
regression coefﬁcient. Thus, if the estimate of b is reduced
by 50%, the corresponding sample size is increased by
approximately fourfold.
Results
GWAS of disease status: psoriasis
We obtained the Perlegen 600 K unﬁltered genotype data
(phg000011, phs000019.v1.p1) from dbGaP (NCBI) and
the IDs of the exact 1,359 cases and 1,400 controls from
Dr. Abecasis and his colleagues http://www.ncbi.nlm.nih.
gov/sites/entrez?Db=gap. Because two cases are not
included in the dbGaP data, our BR-squared analysis was
performed on 1,357 ? 1,400 samples. We excluded
markers with \95% genotype call rate, MAF\1% and
HWE p\10
-6 in controls. In total, 439,496 autosomal
SNPs that passed quality control criteria were used as input
to BR-squared. Bias-reduced estimates were obtained for
the 10 replicated SNPs (Table 1; Fig. 1) and for the nine
failed SNPs (Fig. 2), using 1,000 level 1 bootstrap samples
for the effect estimate and 100 level 2 samples for the
variance estimate, under the ranking criterion that was used
in the original discovery study. Note that BR-squared is
applied to the discovery samples only, and estimates from
the follow-up samples are provided in the ﬁgures and tables
for comparison purposes.
Of the 10 replicated SNPs, we observed[60% reduction
in OR estimates for 8 of them with the bias-adjusted esti-
mates considerably closer to the follow-up estimates than
the naive estimates (Table 1; Fig. 1). In some cases, the
bootstrap method appears to be conservative. However, we
note that the follow-up OR estimates as reported in Nair
et al. (2009) are in fact also subject to the winner’s curse,
albeit less severely, because they were reported only if
supporting evidence for association had been found:
p\0.05 in the follow-up sample and direction of effect
matching the discovery sample. As expected, there was not
much correction for rs12191877 from chromosome 6,
because it is in the well-known MHC/HLA region strongly
associated with psoriasis, and was detected with extremely
high power as reﬂected by the association test p value.
Note that for this study we modelled the ranking effect
alone because the reported SNPs were mostly selected
based on ranks without a statistical signiﬁcance threshold
(Nair et al. 2009). In such a situation, Zhong and Prentice
(2010) suggested using a threshold value of 0.05 for the
likelihood approaches (the likelihood method however
tends to be sensitive to the choice of the threshold value).
For comparison, we calculated the likelihood-based esti-
mate that averages the conditional maximum likelihood
estimate adjusting for a = 0.05 and the mean of the nor-
malized conditional likelihood estimate proposed by Ghosh
et al. (2008). This latter estimator was shown to outperform
other likelihood-based estimators (Ghosh et al. 2008; Faye
et al. 2010). Because it is difﬁcult to specify a joint dis-
tribution for all GWAS SNPs simultaneously, the likeli-
hood method must be applied to one SNP at a time. The
results in Fig. 1 clearly demonstrate that the single-SNP
approach is not adequate for GWAS and multiple corre-
lated SNPs must be considered jointly at the genome-wide
level as implemented in BR-squared.
Interestingly, the bootstrap method appears to be anti-
conservative for the nine SNPs that were not replicated
(Fig. 2) in contrast to the conservative observation made
for the 10 replicated SNPs (Fig. 1). One reason is that BR-
squared treats ‘‘ﬂip-ﬂop’’ estimates [change in the direction
of log(OR)] as evidence for no association and forces the
BR-squared estimate to be zero (Discussion). In addition,
important to note is that the follow-up OR estimates in this
case suffer from what we call the ‘‘loser’s curse’’, because
they were reported only if no supporting association evi-
dence was found, i.e. p[0.05 in the follow-up sample or
direction of effect opposite of the discovery sample. The
results of the BR-squared analysis imply that it might be
premature to conclude false positives for several of the
failed SNPs including rs2273668.
GWAS of a quantitative trait: HbA1c
The genome-wide BR-squared method was applied to the
CONventional treatment group (nCON = 667) with 1,000
level 1 and 100 level 2 bootstrap samples, following the
original selection procedure, i.e. under a signiﬁcance
threshold of 5 9 10
-8 for the p value of an association test
in the linear regression of the average log(HbA1c) value on
an additively coded SNP. In total, 841,342 SNPs with
MAF[1%, HWE p[10
-6, and not signiﬁcantly associ-
ated with gender were analyzed jointly. Application of
550 Hum Genet (2011) 129:545–552
123BR-squared yielded an effect size estimate, bCON.boot-
strap = 0.003 for rs1358030, the only SNP that achieved
genome-wide signiﬁcance in the original GWAS. While
the naive estimate is bCON.naive = 0.045, this bias-reduced
effect estimate is comparable to the value obtained from
independent INT group, bINT = 0.005 (Table 2).
For comparison, we also applied the likelihood-based
method to CON and obtained an estimate of 0.032. This
value is similar to that obtained via the single-locus boot-
strap option in BR-squared (0.037), which ignores the fact
that rs1358030 not only achieved genome-wide signiﬁ-
cance, but its association test statistic was also the largest
among all competing SNPs. Clearly, modelling the
threshold effect alone is not adequate for GWAS, and
considering all SNPs jointly can further reduce the esti-
mation bias considerably.
Discussion
The genome-wide bootstrap is computationally intensive
but nevertheless practically feasible. The total CPU time
required for a typical GWAS (*2,000 individuals, *1M
SNPs) with 1,000 bootstrap samples is less than an hour (4
Amd Opteron CPU at 2.8Ghz and 8 GB RAM), growing
linearly with the number of individuals and SNPs. Esti-
mating the variation of the estimate is more costly because
it requires a two-level nested bootstrap, and the time is
multiplied by the number of level 2 bootstrap samples
(typically 100). For example, the psoriasis application used
a total CPU time of 22 days for both point and CI esti-
mation, and only 45 min for the point estimation alone.
To improve time efﬁciency, we have implemented BR-
squared as a truly distributed application, so that it can
utilize a single computer with multiple CPUs, a heteroge-
neous computer cluster or both at the same time. Therefore,
application of BR-squared for a typical GWAS could be
completed within a day using 20 computers in a cluster, a
reasonable undertaking for most investigators. To further
improve the efﬁciency of the bootstrap calculations, we
also provide an option to use only the top ranked 5–10% of
the original set of GWAS SNPs. For example, in the pso-
riasis application, when only the top 20 K SNPs were eli-
gible for inclusion in the bootstrap averages, 95% of the
bootstrap estimates were within 5.4% of the estimates
using all the SNPs. Using the top 20 K SNPs, the total CPU
time was only 22 h with 1,000 level 1 and 100 level 2
bootstrap samples as compared to 22 days using all
*440 K SNPs. Therefore, the computational time can be
reduced by more than 90% with little compromise in
estimation accuracy.
The bootstrap approach also has the advantage of ﬂex-
ibility and can be readily modiﬁed to reﬂect different
analysis strategies as illustrated by the GWAS of psoriasis
in which selection of SNPs was based on ranks only. BR-
squared also allows selection of SNPs based on the mini-
mum p value of trend and genotypic association tests as
used by the GWAS of the Wellcome Trust Case Control
Consortium (WTCCC 2007).
For many associated SNPs, particularly for those with
p values just below the genome-wide signiﬁcance thresh-
old, we observed [50% reduction in genetic effect esti-
mates, consistent with the value of 60% suggested by
others (Ioannidis et al. 2009; Zhong and Prentice 2010).
Our results lead to a minimal fourfold increase in the
sample size requirement for replication studies, and also
imply that many loci that appeared not to have been rep-
licated may be in fact true positives, but failed to replicate
because the replication sample sizes, and thus power, were
too low. It is therefore crucial to adjust for selection bias
when interpreting whole genome scan ﬁndings and plan-
ning replication and meta-GWAS studies. Our method, BR-
squared, offers a practical solution to the winner’s curse in
genome-wide scans.
The genome-wide bootstrap method tends to be slightly
conservative for true positives, as seen in the applications
herein as well as in simulation studies reported by Faye
et al. (2010). A conservative effect estimate will lead to
over-estimation of necessary replication sample size.
Although sample size over-estimation can result in
unnecessary cost, replication sample size is typically
calculated under a set of ideal assumptions such as using
the same ascertainment strategy as the discovery stage,
samples from a homogenous population, no missing or
bad quality data, etc. In practice, violation of assumptions
might lead to a larger sample size necessary for suc-
cessful replication study. For these reasons, slight con-
servativeness in effect estimation in some situations could
be helpful. Xu et al. (2011) recently showed that there is
no unbiased estimate conditionally on the signiﬁcance of
the corresponding hypothesis test. Therefore, further
improvements in effect estimation likely require addi-
tional information or data. For false positives or SNPs
with effect size close to the null value, the method can be
anticonservative (Fig. 2) due to the ‘‘ﬂip-ﬂop’’ constraint.
Lifting the constraint would improve the performance for
putatively false positive SNPs, but there is a trade-off
between the null and alternative cases. Practically, it is
advantageous for the method to perform better for true
positives: a false-positive SNP can be easily weeded out
in the replication study (e.g. 95% of the time the repli-
cation p value will be[0.05 regardless of the sample size
as long as the p values are calculated properly), but a
truly associated SNP not replicated (say due to insufﬁ-
cient sample size) will not be followed up. In application,
because we do not know the underlying truth between
Hum Genet (2011) 129:545–552 551
123true or false positives, we impose the ‘‘ﬂip-ﬂop’’ con-
straint in the BR-squared implementation.
The phenomenon of the winner’s curse is not limited to
associationstudiesofmaineffects.Infact,thewinner’scurse
can affect all under-powered studies in which the same
observations are used for both effect estimation and hypoth-
esis testing, for example eQTL (Choy et al. 2008), haplotype
association, G 9 Go rG9 E analyses. The winner’s curse
could lead to false-positive interaction studies, for example,
when a signiﬁcantly associated SNP, detected in one group
(e.g. a cohort or a treatment group) is tested for interaction
with another group (Bailey et al. 2009). In that case, because
the effect estimate issubjectto the winner’scurseonly inthe
ﬁrst group, the apparent difference in the main effect esti-
mates between the two groups could be misinterpreted as
evidence for interaction. In principle, the proposed bootstrap
framework can be adapted to address the problem, but the
corresponding implementation is non-trivial and requires
investigation of the speciﬁcs of each setting.
As we move into whole genome sequencing, the number
of tests conducted will increase, but power to detect rare
variants may be only modest. In this setting, the adverse
effectsofthewinner’scursearelikelytobemoresevere,and
methods to reduce bias, such as BR-squared are essential.
URLs: The software package, BR-squared, that provides
bias-reduced estimates via bootstrap re-sampling for gen-
ome-wide association studies of either disease status or
quantitative traits, is available at the website of corre-
sponding author L.S. (http://www.utstat.toronto.edu/sun/).
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